Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more
Mico BioMed Co. Ltd. (214610) - Total Liabilities
Latest total liabilities as of September 2025: ₩7.88 Billion KRW
Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) has total liabilities worth ₩7.88 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mico BioMed Co. Ltd. - Total Liabilities Trend (2015–2024)
This chart illustrates how Mico BioMed Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mico BioMed Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Mico BioMed Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fitzroy Minerals Inc
OTCQB:FTZFF
|
USA | $768.34K |
|
Safe Fertility Group Public Company Limited
BK:SAFE
|
Thailand | ฿213.74 Million |
|
Tryptamine Therapeutics Ltd
AU:TYP
|
Australia | AU$367.88K |
|
Lippo Malls Indonesia Retail Trust
PINK:LPMDF
|
USA | $894.47 Million |
|
Wisr Ltd
AU:WZR
|
Australia | AU$976.80 Million |
|
Sýn hf
IC:SYN
|
Iceland | Ikr22.30 Billion |
|
Herald Holdings Limited
STU:HH3
|
Germany | €291.00 Million |
|
GMM Grammy Public Company Limited
BK:GRAMMY
|
Thailand | ฿4.10 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Mico BioMed Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mico BioMed Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mico BioMed Co. Ltd. (2015–2024)
The table below shows the annual total liabilities of Mico BioMed Co. Ltd. from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩28.58 Billion | +14.38% |
| 2023-12-31 | ₩24.99 Billion | -37.24% |
| 2022-12-31 | ₩39.82 Billion | +9.34% |
| 2021-12-31 | ₩36.42 Billion | +142.82% |
| 2020-12-31 | ₩15.00 Billion | -37.53% |
| 2019-12-31 | ₩24.01 Billion | +30.16% |
| 2018-12-31 | ₩18.45 Billion | +41.64% |
| 2017-12-31 | ₩13.02 Billion | +130.32% |
| 2016-12-31 | ₩5.65 Billion | +0.74% |
| 2015-12-31 | ₩5.61 Billion | -- |